Cookies on PerkinElmer
PerkinElmer uses cookies to ensure that we give you the best experience possible on our website. This may include cookies from third party websites. If you continue without changing your settings, we will assume that you consent to receive cookies from this website. You can change your cookie settings at any time. To learn more, please review our cookie policy, which includes information on how to manage your cookies.

Overview of Pre-eclampsia


Use Your Existing Aneuploidy Screening System To Achieve More

PerkinElmer is complementing its full range of effective prenatal screening assays by providing new assays for pre-eclampsia risk assessment. Pre-eclampsia is one of the most common of the serious complications of pregnancy. It affects the mother, the unborn baby and the neonate. Early identification of women at high risk for pre-eclampsia is an important step towards improving the outcome of pregnancies and preventing pre-eclampsia.

Towards Screening For Early-Onset Pre-eclampsia

Our intense research activities in the collaboration with leading experts has led to identification of biomarkers that may facilitate a more effective method of screening for pre-eclampsia, when combined with established risk factors and biophysical markers. PerkinElmer has launched the first placental growth factor (PlGF) assay* to be used as an aid in screening pregnant women for early-onset pre-eclampsia.

A diagnosis of pre-eclampsia is based on symptoms presenting from the disease. In contrast, pre-eclampsia screening involves estimating, before any symptoms appear, the risk that the disorder will develop. Screening allows early identification of a woman at high-risk for pre-eclampsia, and increases the likelihood of a better pregnancy outcome.

Watch a video about pre-eclampsia screening (Fetal Medicine Foundation)

Towards Effective Pre-eclampsia Screening

The traditional method for screening for pre-eclampsia is maternal history*. However, screening on such a basis provides poor sensitivity and specificity (about 30 % detection rate with 5 % false positive rate). Far better performance in early-onset pre-eclampsia detection is attainable by combining maternal history with other serum and ultrasound marker results.  According to recent studies, appropriate choice of markers can yield detection rates of 93% or higher for a false positive rate of 5%.

Parameters Maternal history & characteristics with:Early PE <34 weeksAll PE <42 weeks
FPR 5%FPR 10%FPR 5%FPR 10%
PlGF &PAPP-A60%74%30%41%
PlGF, uAD &MAP87%96%36%60%
PAPP-A, uAD &MAP82%93%38%53%
PlGF, PAPP-A, uAD &MAP93%96%38%54%

Values from Akolekar et al (2013) Fetal Diagn Ther 33:8-15

Screening Differs From Diagnosis

Detection rates for early-onset pre-eclampsia as estimated for various combinations of markers. The utility of maternal serum PlGF has been confirmed in several studies, and it has also been shown to be a more discriminating marker than PAPP-A. However, a number of studies confirm the benefit of including both of these serum markers.

MAP= Mean Arterial Pressure
uAD= uterine artery Doppler pulsatility index 
PAPP-A = Pregnancy-Associated Plasma Protein-A
PlGF = Placental Growth Factor

*The maternal history and characteristics include age, racial origin, method of conception, smoking, chronic diseases such as chronic hypertension, previous or family history of pre-eclampsia, parity (parous or nulliparous). 


PerkinElmer products for pre-eclampsia are not available in all countries. For information on availability please contact your local sales representative.

Information provided within the Overview of Pre-eclampsia is for information purposes only and not intended to be construed as medical guidance. Always contact your healthcare professional for assessment and direction regarding your health.